The aim of this work was to estimate the magnitude of the differential impacts of initial treatment status relative to the impact of classic clinicopathologic factors on the long-term overall survival (OS) of sarcoma patients in a referral cancer center.
From the institutional database, we identified 2185 patients who presented to the institutional multidisciplinary team (MDT) prior to (N = 717, 32.8%) or after (N = 1468, 67.2%) initial treatment, with a first diagnosis of sarcoma from January 1999 to December 2018. Descriptive, univariate and multivariate analyses were applied to identify the factors related to OS. By performing propensity score matching of each completely MDT-treated patient to a referral patient with similar characteristics, the differential impacts of the identified risk and prognostic factors on OS in the 2 groups were estimated by the Kaplan‒Meier survival curves, log-rank test and Cox proportional hazard regression; the results were compared using calibrated nomograph models and forest plots.
Adjusted for the clinicopathologic factors of patient age, sex, primary site, tumor grade, tumor size, resection margin and histology, hazard ratio-based modeling analysis indicated that the initial treatment status was an independent but intermediate prognostic factor associated with long-term OS. The major impacts of the initial and comprehensive MDT-based management on significant improvement of the 20-year OS of sarcomas were reflected in the subgroup of patients with stromal, undifferentiated pleomorphic, fibromatous, fibroepithelial, or synovial neoplasms and tumors in the breast, gastrointestinal tract, or soft tissues of limb and trunk.
This retrospective study supports early referral of patients with soft tissue masses of unknown identity to a specialized MDT before biopsy and initial resection to reduce the risk of death but highlights an unmet need for a greater understanding of some of the most difficult sarcoma subtypes and subsites and their management.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Surgical Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The 2020 WHO classification of tumors of soft tissue: selected changes and new entities.Adv Anat Pathol. 2021 Jan; 28: 44-58
- Cancer statistics, 2022.Ca - Cancer J Clin. 2022 Jan; 72: 7-33
- Cancer statistics for adolescents and young adults, 2020.Ca - Cancer J Clin. 2020 Nov; 70: 443-459
- Comprehensive and integrated genomic characterization of adult soft tissue sarcomas.Cell. 2017 Nov 2; 171: 950-965
- Undifferentiated sarcomas develop through distinct evolutionary pathways.Cancer Cell. 2019 Mar 18; 35: 441-456
- Sarcomas associated with genetic cancer predisposition syndromes: a review.Oncol. 2016 Aug; 21: 1002-1013
- Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study.Lancet Oncol. 2016 Apr; 17: 532-538
- Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine.Ca - Cancer J Clin. 2020 May; 70: 200-229
- Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology.J Natl Compr Cancer Netw. 2022 Jul; 20: 815-833
- Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021 Nov; 32: 1348-1365
- Radiation therapy for treatment of soft tissue sarcoma in adults: executive summary of an ASTRO clinical practice guideline.Pract Radiat Oncol. 2021 Sep-Oct; 11: 339-351
- Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET).Ann Oncol. 2013 Jun; 24: 1685-1691
- Improved survival using specialized multidisciplinary board in sarcoma patients.Ann Oncol. 2017 Nov 1; 28: 2852-2859
- NETSARC/REPPS/RESOS and French Sarcoma Group–Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) Networks. Surgery in reference centers improves survival of sarcoma patients: a nationwide study.Ann Oncol. 2019 Jul 1; 30: 1143-1153
- The prognostic impact of unplanned excisions in a cohort of 728 soft tissue sarcoma patients: a multicentre study.Ann Surg Oncol. 2017 Jun; 24: 1596-1605
- Re-excision after unplanned excision of soft tissue sarcoma: a systematic review and metanalysis. The rationale of systematic re-excision.J Orthop. 2021 May 14; 25: 244-251
- Postoperative nomogram for 12-year sarcoma-specific death.J Clin Oncol. 2002; 20: 791-796
- Soft tissue sarcoma nomograms and their incorporation into practice.Cancer. 2017 Aug 1; 123: 2802-2820
- Molecular classification of soft tissue sarcomas and its clinical applications.Int J Clin Exp Pathol. 2010 Apr 23; 3: 416-428
- Soft tissue sarcomas with complex genomic profiles.Virchows Arch. 2010 Feb; 456: 201-217
- Advances in sarcoma gene mutations and therapeutic targets.Cancer Treat Rev. 2018 Jan; 62: 98-109
- GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research). GEIS guidelines for gastrointestinal sarcomas (GIST).Cancer Treat Rev. 2017 Apr; 55: 107-119
- Influence of unplanned excisions on the outcomes of patients with stage III extremity soft-tissue sarcoma.Cancer. 2018 Oct 1; 124: 3868-3875
- The impact of re-excision of inadequately resected soft tissue sarcomas on surgical therapy, results, and prognosis: a single institution experience with 682 patients.J Surg Oncol. 2010 Nov 1; 102: 626-633
- Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence.Ann Surg Oncol. 2010 Aug; 17: 2102-2111
- Defining which patients are at high risk for recurrence of soft tissue sarcoma.Curr Treat Options Oncol. 2020 May 27; 21: 56
- Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.Cancer Sci. 2018 Jun; 109: 1743-1752
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.Nat Genet. 2010 Aug; 42: 715-721
- Homologous recombination repair deficiency as a therapeutic target in sarcoma.Semin Oncol. 2020 Dec; 47: 380-389
- Rapid evolution of mutation rate and spectrum in response to environmental and population-genetic challenges.Nat Commun. 2022 Aug 13; 13: 4752
- Debris-stimulated tumor growth: a Pandora's box?.Cancer Metastasis Rev. 2021 Sep; 40: 791-801
- Everything you always wanted to know about evaluating prediction models (but were too afraid to ask).Urology. 2010 Dec; 76: 1298-1301
- Nomograms in oncology: more than meets the eye.Lancet Oncol. 2015 Apr; 16: e173-e180
- Taiwan's nationwide cancer registry system of 40 years: past, present, and future.J Formos Med Assoc. 2019 May; 118: 856-858
- Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis.Cancers (Basel). 2021 Sep 26; 13: 4816
Published online: May 03, 2023
Accepted: May 2, 2023
Received in revised form: April 7, 2023
Received: January 30, 2023
Publication stageIn Press Journal Pre-Proof
© 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.